Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage pharmaceutical company whose news flow centers on the development of next-generation pain and central nervous system therapeutics that incorporate built-in abuse and overdose protection. Company updates frequently highlight progress across its proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) platforms, which are designed to create tamper-resistant prodrugs and overdose-protected medications.
Investors and healthcare observers following ENSC news can expect regular coverage of clinical milestones for PF614, the company’s TAAP™ extended-release oxycodone analogue for moderate to severe pain, including pivotal Phase 3 trial activities and regulatory interactions with the U.S. Food and Drug Administration. News items also describe the evolution of PF614-MPAR, which combines PF614 with MPAR® overdose protection and is advancing under FDA Breakthrough Therapy designation with support from multi-year NIDA grants.
Beyond pain management, Ensysce news includes developments in its ADHD pipeline, such as patent notices for PF8026, an immediate-release amphetamine prodrug that uses TAAP™ and MPAR® technologies to address stimulant abuse and overdose risk. Updates on PF9001, the company’s lead opioid use disorder candidate supported by a HEAL grant, also appear in the company’s communications.
Additional ENSC news covers intellectual property achievements extending MPAR® patent protection, federal grant awards, symposium presentations at major pain conferences, and financing transactions such as preferred stock offerings and registered direct offerings disclosed via SEC filings and press releases. This news page aggregates these announcements so readers can track Ensysce’s clinical, regulatory, intellectual property, and capital markets developments in one place.
Ensysce Biosciences (NASDAQ:ENSC) initiated a live "Ask Me Anything" (AMA) session on March 4, 2026 to discuss strategic execution, regulatory risk mitigation, and pipeline prioritization for PF614.
The AMA featured CEO Dr. Lynn Kirkpatrick addressing Phase 3 sequencing, capital discipline, commercial potential for PF614, and next steps; a replay is available on the company website.
Ensysce Biosciences (NASDAQ:ENSC) announced the peer-reviewed publication of Phase 1 clinical data for PF614-MPAR, an oxycodone prodrug using MPAR® technology that limits oral overdose while preserving therapeutic opioid exposure.
Findings show appropriate plasma levels at normal dosing and prevention of large opioid increases at supratherapeutic doses; MPAR received FDA Breakthrough designation in January 2024 and IP extends through 2042.
Ensysce Biosciences (NASDAQ:ENSC) announced on February 25, 2026 that its Board has launched a formal review of strategic alternatives to enhance shareholder value. The review may include partnerships, licensing, capital formation, business combinations, asset sales, or other corporate transactions.
The company said there is no timetable and no assurance a transaction will result; further disclosure will occur only if the Board approves a transaction or is required by law. Leadership emphasized continued focus on advancing TAAP™ and MPAR® platforms.
Ensysce Biosciences (NASDAQ:ENSC) announced executive presentations at four scientific and industry events in March–June 2026, highlighting its PF614 and PF614-MPAR programs and TAAP/MPAR platforms. Company executives will discuss emerging clinical data, development strategy, abuse-reduction approaches, and commercial launch best practices.
Key dates: USASP Mar 23-26, 2026; European Pain Summit May 7-8, 2026; Commercial Excellence Lab Jun 3-4, 2026; CPDD Jun 13-17, 2026.
Ensysce Biosciences (NASDAQ:ENSC) announced it has enrolled 50% of subjects targeted for interim review in the pivotal Phase 3 PF614-301 trial as of January 28, 2026. Enrollment began in late December 2025 across three U.S. sites, with interim data expected after the planned review.
PF614 is a twice-daily, activation‑dependent opioid candidate engineered for extended pain relief with built-in abuse and tamper protection.
Ensysce Biosciences (NASDAQ:ENSC) announced on January 21, 2026 that the Brazilian Patent Office issued a Notice of Allowance for a patent (PI0919711-7) covering additional opioid families that use the company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.
The allowed patent includes both composition of matter and method of use claims, and the company says this expands its global intellectual property protection for next-generation analgesics, complementing existing allowances in North America, the EU, and South America. Management framed the development as strengthening its pain portfolio and advancing safer opioid formulations without compromising pain relief.
Ensysce Biosciences (NASDAQ:ENSC) received a Notice of Allowance from the European Patent Office for a patent covering PF8026, an immediate-release amphetamine prodrug using the company's TAAP™ and MPAR® technologies for built-in abuse and overdose protection. The allowed claims cover composition of matter and method of use, expanding Ensysce's ADHD portfolio alongside PF8001 (extended release). The release highlights that MPAR® overdose protection has been validated in clinical studies and cites a 2023 figure of ~3.9 million people aged 12+ who misused prescription stimulants, framing the program as addressing misuse and overdose risk.
Ensysce Biosciences (NASDAQ:ENSC) issued its 2025 annual shareholder letter outlining clinical, regulatory, IP and financing progress. Key 2025 achievements include initiation of the pivotal PF614-301 Phase 3 trial with enrollment started at two sites, FDA alignment on PF614 commercial manufacturing and CMC strategy, and advancement of PF614-MPAR under Breakthrough Therapy pathway. The company secured additional capital including a November 2025 $4M convertible preferred financing enabling access to up to $20M over 24 months and continued non-dilutive support from NIDA totaling over $25M for MPAR programs. A new MPAR patent allowance extends protection through 2042. Anticipated 2026 priorities include continued Phase 3 enrollment, further FDA interactions, MPAR labeling work, and PF9001 IND-enabling activities.
Ensysce Biosciences (NASDAQ:ENSC) announced the enrollment of the first patient in its pivotal Phase 3 trial of PF614 on December 9, 2025. The study, PF614-301, is a multicenter, randomized, double‑blind, placebo‑ and active‑controlled trial evaluating PF614 for moderate to severe pain after abdominoplasty.
The trial will test twice‑daily dosing intended to provide consistent post‑surgical analgesia while incorporating an innovative chemical mechanism designed to reduce abuse and overdose risk. Initial sites include CenExel JBR in Salt Lake City and CenExel Atlanta under principal investigators Dr. Todd Bertoch and Dr. Jessica McCoun.
Ensysce Biosciences (NASDAQ:ENSC) announced a U.S. Notice of Allowance for a new patent covering its MPAR® overdose protection technology, extending MPAR patent coverage through 2042. The patent titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof" includes composition-of-matter and method-of-use claims to strengthen the company’s IP estate. MPAR earned Breakthrough Therapy Designation from the FDA in January 2025. Clinical testing of PF614-MPAR reportedly showed effective pain relief when taken as prescribed and reduced excessive opioid delivery when multiple doses were taken. Ensysce is also applying MPAR to other drug classes and is conducting a second clinical trial to further evaluate the technology.